ResMed (ASX:RMD) Falls Despite Earnings Beat: Buy the Dip?

ResMed (ASX:RMD) just delivered what looked like a great quarter. Revenue jumped 11%, earnings climbed 21%, and the company beat analyst expectations. On paper, this should have been a green day for the share price. Instead, RMD shares dropped on Friday and ended the week lower.

So what’s going on? When a company posts strong numbers, but the stock still falls, it usually means investors are worried about something else. In ResMed’s case, there are a few moving parts behind the reaction. The good news is that none of these points indicates that the business is in trouble. The harder question is whether this dip is a real buying opportunity or whether the stock has more pain ahead. Here’s our take.

What are the Best ASX Stocks to invest in right now?

Why the Quarter Was Actually Strong

Let’s keep this simple. ResMed makes the machines and masks that help people with sleep apnoea breathe properly at night, and it’s the global leader in this space. Demand is clearly still growing; mask and accessories sales rose 12% globally, profit margins expanded nicely, and the company generated more than half a billion US dollars in cash from operations in just three months.

Even better, ResMed has now lifted its dividend for 14 years in a row. That’s a track record only genuinely strong businesses can deliver. The company also returned over US$260 million to shareholders this quarter through buybacks and dividends. In our view, the underlying business is firing on all cylinders. None of the weakness in the share price is due to operational problems.

Why the Market Is Still Nervous

So why is the market unhappy? Three reasons stand out.

First, ResMed is spending around US$340 million (roughly A$520 million) to buy a US company called Noctrix Health, which makes a wearable device for restless legs syndrome. Acquisitions can be exciting long-term, but they often weigh on profits in the short term. Some investors don’t like that uncertainty.

Second, long-time CFO Brett Sandercock is retiring, with Aaron Bloomer stepping in. There’s no specific reason to worry, but markets always get a little nervous during leadership changes.

Third, and most importantly in our view, there’s the ongoing fear about weight-loss drugs like Ozempic. Some investors worry these drugs will shrink the future sleep apnoea market by tackling obesity, the condition’s main driver. We believe this concern is overdone. ResMed’s own data actually shows patients using both weight-loss drugs and CPAP machines stay on therapy longer, not shorter.

The Investor’s Takeaway for ResMed

Here’s how we’d think about it. ResMed is a quality business that’s growing, generating strong cash flow, and rewarding shareholders consistently. The latest quarter confirmed all of that. The reasons the share price is falling have more to do with investor mood than anything actually going wrong inside the company. That kind of setup can create opportunity. With shares 36% off their highs and expectations reset, the risk-reward now looks more favourable than it has in months.

Still, we’d be cautious about chasing too hard. The risks are real, even if we think they’re overstated. For existing holders, we’d hold. For new investors, this weakness is a better entry point than chasing a stock that’s running, but easing in gradually beats going all-in today.